{"entity":{"id":"nct00883116","kind":"trial","name":"A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer","aka":["IXAMPLE2"],"tldr":"A phase 3 trial of Ixabepilone, Doxorubicin and Paclitaxel / nab-paclitaxel in Endometrial cancer, run by R-Pharm, recorded as terminated on the registry.","summary":"A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer is a phase 3 interventional study registered as NCT00883116 by R-Pharm, with 551 participants recorded, started 2009-08 and due to reach its primary completion in 2012-06. Interventions recorded: Ixabepilone, Doxorubicin, Paclitaxel. Conditions recorded: Endometrial Cancer.\n\nLinked to the drug Ixabepilone because the registry names it among its interventions and Endometrial cancer among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT00883116","url":"https://clinicaltrials.gov/study/NCT00883116"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["endometrial","advanced-recurrent-endometrial-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["ixabepilone","doxorubicin","paclitaxel"],"companies":["r-pharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00883116","phase":"3","setting":"A Phase III, Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women With Advanced Endometrial Cancer Who Have Previously Been Treated With Chemotherapy","sponsor":"R-Pharm","started":"2009-08","yearReported":2014,"enrolled":551,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall Survival (OS)","primary":true,"unit":"months","arms":[{"name":"Ixabepilone, 40 mg/m^2, Intravenously (IV)","n":248,"value":10.9,"note":"95% CI 8.5 to 12.7; Figures from the ClinicalTrials.gov results section (first posted 2014-03-14), not from a publication"},{"name":"Control With Chemotherapy (Paclitaxel or Doxorubicin)","n":248,"value":12.3,"note":"95% CI 10.7 to 15.4"}],"hr":1.3,"ci":[1,1.7],"p":"0.0397","source":"https://clinicaltrials.gov/study/NCT00883116?tab=results"},{"endpoint":"Progression-free Survival","unit":"months","arms":[{"name":"Ixabepilone, 40 mg/m^2, Intravenously (IV)","n":223,"value":3.4,"note":"95% CI 2.8 to 4.2; Figures from the ClinicalTrials.gov results section (first posted 2014-03-14), not from a publication"},{"name":"Control With Chemotherapy (Paclitaxel or Doxorubicin)","n":223,"value":4,"note":"95% CI 2.7 to 4.3"}],"hr":1,"ci":[0.8,1.3],"p":"0.8011","source":"https://clinicaltrials.gov/study/NCT00883116?tab=results"},{"endpoint":"Best Overall Response Rate","unit":"%","arms":[{"name":"Ixabepilone, 40 mg/m^2, Intravenously (IV)","n":223,"value":15.2,"note":"95% CI 10.8 to 20.6; Figures from the ClinicalTrials.gov results section (first posted 2014-03-14), not from a publication"},{"name":"Control With Chemotherapy (Paclitaxel or Doxorubicin)","n":223,"value":15.7,"note":"95% CI 11.2 to 21.1"}],"source":"https://clinicaltrials.gov/study/NCT00883116?tab=results"}]},"route":"/trials/nct00883116/","neighbours":{"cancer":[{"id":"advanced-recurrent-endometrial-cancer","kind":"cancer","name":"Advanced or recurrent endometrial cancer","route":"/cancers/advanced-recurrent-endometrial-cancer/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"}],"drug":[{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"ixabepilone","kind":"drug","name":"Ixabepilone","route":"/drugs/ixabepilone/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"}],"company":[{"id":"r-pharm","kind":"company","name":"R-Pharm","route":"/companies/r-pharm/"}]}}